Company intelligence / Profile preview

BioZyme

St. Joseph, Missouri, United Statesbiozymeinc.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioZyme has over seven decades of research-driven innovation in animal nutrition. Its proprietary AO-Biotics Amaferm ingredient has been validated in more than 175 published studies to improve digestibility and overall wellness across cattle, swine, poultry, sheep, goats, horses, dogs, cats and more. The company’s supplements are widely used globally for improved animal performance.

Therapeutic areas: GastroenterologyMetabolic DisordersOther
Modalities: PrebioticPost-bioticFeed additive
Industry: Veterinary

Drug pipeline

2 assets

Amaferm

Commercial

Indications: Animal nutrition

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioZyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioZyme.

Explore the full profile